Checklist 1: checklist before prescribing Amfexa® 5 mg, 10 mg and 20 mg Tablets

Checklist 2: checklist for monitoring of ongoing therapy with Amfexa® 5 mg, 10 mg and 20 mg Tablets

Considerations when ending treatment with Amfexa ® 5 mg, 10 mg and 20 mg Tablets

Due to the stimulant properties of dexamfetamine sulfate and the frequent presence of comorbidities associated with ADHD, it is important that dexamfetamine sulfate products be used consistently and only for the appropriate patients. The accompanying materials were developed by one of the dexamfetamine sulfate product manufacturers to facilitate awareness and adoption of recommendations for the use of dexamfetamine sulfate. It is recommended that these materials be used in conjunction with the SmPC for the individual product that is being prescribed.

Information for parents and carers of patients prescribed Amfexa 5mg, 10mg and 20mgs tablets

This sheet provides additional information for pharmacists on Amfexa® 5 mg, 10 mg and 20 mg Tablets (dexamfetamine sulfate).

A physician’s guide to prescribing Amfexa® 5 mg, 10 mg and 20 mg Tablets (dexamfetamine sulfate)

This chart is mainly intended to assess the growth of school age boys. It combines data from the UK 1990 growth reference for children at birth and from 4 -18 years(1), with the WHO growth standard for children aged 2 years to 4 years(2). The growth of children under 2 years of age should be plotted on the more detailed UK-WHO 0-4 years growth charts.

A form template according to prescribing information in more detail, growth, psychiatric and cardiovascular status should be regularly monitored

This chart is mainly intended to assess the growth of school age girls. It combines data from the UK 1990 growth reference for children at birth and from 4 -18 years(1), with the WHO growth standard for children aged 2 years to 4 years(2). The growth of children under 2 years of age should be plotted on the more detailed UK-WHO 0-4 years growth charts.